Hoe is Oren Shuster's beloning veranderd ten opzichte van IM Cannabis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$14m
Mar 31 2024	n/a	n/a	-CA$15m
Dec 31 2023	CA$808k	CA$476k	-CA$9m
Sep 30 2023	n/a	n/a	-CA$15m
Jun 30 2023	n/a	n/a	-CA$17m
Mar 31 2023	n/a	n/a	-CA$17m
Dec 31 2022	CA$2m	CA$506k	-CA$23m
Sep 30 2022	n/a	n/a	-CA$22m
Jun 30 2022	n/a	n/a	-CA$16m
Mar 31 2022	n/a	n/a	-CA$10m
Dec 31 2021	CA$2m	CA$516k	CA$91k
Sep 30 2021	n/a	n/a	-CA$10m
Jun 30 2021	n/a	n/a	-CA$12m
Mar 31 2021	n/a	n/a	-CA$24m
Dec 31 2020	CA$742k	CA$424k	-CA$29m
Sep 30 2020	n/a	n/a	-CA$7m
Jun 30 2020	n/a	n/a	-CA$10m
Mar 31 2020	n/a	n/a	-CA$982k
Dec 31 2019	CA$2m	CA$357k	-CA$7m

Compensatie versus markt: De totale vergoeding ($USD 598.94K ) Oren } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Oren is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Oren Shuster

5yrs

Tenure

CA$808,068

Compensatie

Mr. Oren Shuster serves as the Co-owner of IMC Ltd. Mr. Shuster serves as Chief Executive Officer and Director of IM Cannabis Corp. since October 11, 2019. Mr. Shuster is a leading figure in the medical ca...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Oren Shuster	CEO & Director	5yrs	CA$808.07k	13.98% CA$ 689.9k
Uri Birenberg	Chief Financial Officer	less than a year	CA$325.72k	geen gegevens
Richard Balla	Chief Executive Officer of Adjupharm	4.8yrs	CA$293.97k	0.039% CA$ 1.9k
Anna Taranko	Director Investor & Public Relations	no data	geen gegevens	geen gegevens
Michal Nissimov	General Counsel	1.5yrs	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van IMCC wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Oren Shuster	CEO & Director	5yrs	CA$808.07k	13.98% CA$ 689.9k
Shmulik Arbel	Director	less than a year	geen gegevens	geen gegevens
Mordechai Marcus	Independent Director	2.1yrs	CA$96.66k	geen gegevens
Brian Schinderle	Independent Director	3.7yrs	CA$135.32k	geen gegevens
Einat Zakariya	Independent Director	2.1yrs	CA$93.16k	0.46% CA$ 22.5k

2.1yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van IMCC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

IM Cannabis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

IM Cannabis Corp. Appoints Shmulik Arbel to Board of Directors

IM Cannabis Corp. Announces Executive Changes

IM Cannabis Corp., Annual General Meeting, Dec 06, 2023

IM Cannabis Corp. Announces Departure of Itay Vago as CFO

High number of new directors

High number of new directors

Recent updates

IM Cannabis Corp. announced that it expects to receive $1.613 million in funding

IM Cannabis Corp. Appoints Shmulik Arbel to Board of Directors

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding

First quarter 2024 earnings released: CA$0.42 loss per share (vs CA$0.027 profit in 1Q 2023)

IM Cannabis Corp. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS misses analyst expectations

IM Cannabis Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction.

New major risk - Share price stability

IM Cannabis Announces Receipt of Court Action

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Q3, 2023 Results on Nov 13, 2023

IM Cannabis Corp. Announces Executive Changes

IM Cannabis Corp., Annual General Meeting, Dec 06, 2023

IM Cannabis Corp. Announces Departure of Itay Vago as CFO

New major risk - Market cap size

IM Cannabis Corp. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Financial position

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Corp. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis Corp. Commences Exit of Canadian Cannabis Market to Focus its Resources on Pursuing Growth Opportunities in Israel, Germany and Europe

IM Cannabis Corp. to Report Q3, 2022 Results on Nov 14, 2022

High number of new directors

High number of new directors

CEO & Director recently bought US$118k worth of stock

Executive Chairman recently bought US$80k worth of stock

IM Cannabis Corp. Announces Board Changes

IM Cannabis Shareholder Rafael Gabay raises stake

IM Cannabis Corp. announced that it expects to receive $5 million in funding

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M

IM Cannabis Corp., Annual General Meeting, Oct 20, 2022

IM Cannabis Corp. to Report Q2, 2022 Results on Aug 15, 2022

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement

First quarter 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis Corp. Provides Preliminary Unaudited Revenue Guidance for the Second Quarter 2022

IM Cannabis Corp. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

CEO & Director recently bought US$336k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IM Cannabis Corp. Provides Earnings Guidance for Fourth Quarter of 2021 and Full Year 2022

Third quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.017 profit in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Insider recently sold US$60k worth of stock

Second quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in 2Q 2020)

cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets

IM Cannabis Corp. Unveils Proprietary Data from A Clinical Survey Evaluating Medicinal Cannabis Therapy

First quarter 2021 earnings released: EPS CA$0.11 (vs CA$0.011 loss in 1Q 2020)

IM Cannabis Corp. Provides Earnings Guidance for the Second Quarter of 2021

IM Cannabis proposes public offering of securities

IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia

Full year 2020 earnings released: CA$0.74 loss per share (vs CA$0.23 loss in FY 2019)

IM Cannabis Corp. Provides Preliminary Earnings Guidance for the First Quarter and Second Quarter of 2021

IM Cannabis Corp. (CNSX:IMCC) completed the acquisition of Trichome Financial Corp. (CNSX:TFC) from Cresco Labs Inc., Opaskawayak Cree Nation and others.

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp. to Bring Canadian Premium Indoor High-THC Medical Cannabis to Israel with Imports from GTEC Holdings Ltd

New 90-day high: US$10.26

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp Announce That the Israeli Ministry of Health Has Launched A New Pilot Program

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam